pharma news today obesity drugs glp-1 september 2025 Anti-Obesity Drug Market Outlook 2025–2032: Strong CAGR of 18.01% with USD 82.55 Billion Valuation GLP-1 prescriptions for weight loss

Tirzepatide, the first approved dual GIP/GLP-1 receptor agonist, is a 39-amino acid peptide with an approximately 120-hour half-life supporting once-weekly dosing

This darkening is caused by an increase in melanin

KLOW blend is supplied strictly for laboratory research and investigational purposes only

We hypothesized that the difference in CVD phenotypes elicited by AF P might be mediated in part by this subset of gut microbiota-derived products, we performed targeted LC-MS/MS analyses with this panel and identified a notable signal in the circulating levels of PAGln among mice exposed to alcohol

elegans through the deep sequencing ( Drosophila through the screening of cell proliferation-regulating miRNAs